The top gastroenterology biosimilar news from 2024 highlight fluctuations in the adalimumab biosimilar market throughout the ...

The top legal stories in biosimilars from 2024 emphasize the ongoing struggle between ensuring timely patient access and ...

Strengthening the Supply Chain: Key Insights From FDA Commissioner Dr Robert Califf ...

Elie Bahou, PharmD, senior vice president and system chief pharmacy officer at Providence, discusses strategies to improve equitable access to biologic therapies, including tiered formularies, ...

The top gastroenterology biosimilar news from 2024 highlight fluctuations in the adalimumab biosimilar market throughout the ...

Number 5: The impact of pharmaceutical companies' evergreening strategies on the adoption of trastuzumab biosimilars in the Netherlands led to significant price reductions and increased market share.

China's trastuzumab biosimilar market is growing but lags behind European countries, with biosimilars gradually increasing ...

A systematic review identified 13 strategies, including patient and provider education, empathetic communication, and shared ...

The FDA approved Celltrion's Steqeyma (ustekinumab-stba), making it the seventh biosimilar slated to compete against blockbuster Stelara (reference ustekinumab) in 2025. The FDA has approved Steqeyma ...